Walleye Trading
NBIX icon

Walleye Trading’s Neurocrine Biosciences NBIX Stock Holding History

Walleye Trading’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Sell
1,200
-497
-29% -$73.7K ﹤0.01% 3130
2026
Q1 		$224K Buy
1,697
+1,197
+239% +$159K ﹤0.01% 3056
2025
Q4 		$70.9K Buy
+500
New +$72.4K ﹤0.01% 3859
2025
Q1 		– Sell
-1,988
Closed -$271K – 4492
2024
Q4 		$271K Buy
1,988
+1,549
+353% +$192K ﹤0.01% 3054
2024
Q3 		$50.6K Buy
+439
New +$60.2K ﹤0.01% 3535
2024
Q2 		– Sell
-40
Closed -$5.52K – 4705
2024
Q1 		$5.52K Buy
+40
New +$5.46K ﹤0.01% 4406
2022
Q2 		– Sell
-6,519
Closed -$611K – 5491
2022
Q1 		$611K Buy
6,519
+4,573
+235% +$388K ﹤0.01% 2703
2021
Q4 		$166K Buy
1,946
+1,499
+335% +$138K ﹤0.01% 4051
2021
Q3 		$43K Sell
447
-2,366
-84% -$223K ﹤0.01% 4677
2021
Q2 		$274K Sell
2,813
-454
-14% -$43.5K ﹤0.01% 3596
2021
Q1 		$318K Buy
3,267
+1,974
+153% +$207K ﹤0.01% 3162
2020
Q4 		$124K Sell
1,293
-4,683
-78% -$452K ﹤0.01% 3819
2020
Q3 		$575K Buy
+5,976
New +$691K ﹤0.01% 2122
2020
Q2 		– Sell
-32,262
Closed -$3.57M – 4480
2020
Q1 		$2.79M Buy
32,262
+31,468
+3,963% +$3.08M 0.02% 645
2019
Q4 		$85K Buy
+794
New +$83.1K ﹤0.01% 3627
2019
Q1 		– Sell
-13,400
Closed -$1.12M – 4569
2018
Q4 		$957K Buy
13,400
+12,179
+997% +$1.17M 0.01% 1757
2018
Q3 		$150K Buy
+1,221
New +$139K ﹤0.01% 3956
2017
Q2 		– Sell
-75
Closed -$3K – 4792
2017
Q1 		$3K Buy
+75
New +$3.21K ﹤0.01% 4518
2016
Q1 		– Sell
-100
Closed -$6K – 5670
2015
Q4 		$6K Buy
+100
New +$5.08K ﹤0.01% 4883
2015
Q3 		– Sell
-200
Closed -$10K – 5330
2015
Q2 		$10K Buy
+200
New +$8.48K ﹤0.01% 4306

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Trading's NBIX Position: Q2 2026 in Review

Walleye Trading reduced its Neurocrine Biosciences (NBIX) stake by 29% in Q2 2026, selling an estimated $73.7K and leaving 1,200 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #3130.

Walleye Trading first reported a position in NBIX in Q2 2015 and has held it in 20 quarters since. The position peaked at $2.79M in Q1 2020. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Walleye Trading held 1,200 shares of Neurocrine Biosciences worth $202K as of Q2 2026.
  • Walleye Trading sold 497 Neurocrine Biosciences shares in Q2 2026, an estimated $73.7K.
  • Neurocrine Biosciences made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #3130 holding.
  • Walleye Trading first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 20 quarters since.
  • Walleye Trading's Neurocrine Biosciences position peaked at $2.79M in Q1 2020.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.